ChemoCentryx Inc. (CCXI)

9.27
0.20 2.10
NASDAQ : Health Technology
Prev Close 9.47
Open 9.39
Day Low/High 8.77 / 9.52
52 Wk Low/High 5.42 / 10.79
Volume 75.73K
Avg Volume 166.60K
Exchange NASDAQ
Shares Outstanding 48.77M
Market Cap 437.44M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For ChemoCentryx (CCXI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ChemoCentryx Enters Oversold Territory (CCXI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase ChemoCentryx At $8, Earn 14.4% Annualized Using Options

Commit To Purchase ChemoCentryx At $8, Earn 14.4% Annualized Using Options

Investors considering a purchase of ChemoCentryx, Inc. shares, but cautious about paying the going market price of $9.08/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Commit To Buy ChemoCentryx At $6, Earn 17.6% Annualized Using Options

Investors considering a purchase of ChemoCentryx, Inc. stock, but cautious about paying the going market price of $6.88/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer

ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer

Company Reports at ASCO 2017 Gastrointestinal Cancers Symposium 24 Week Progression-Free Survival and 48 Week Overall Survival Data as it Continues to Follow Progress in Study Patients

TheStreet Quant Rating: D (Sell)